Multiparticulate oral formulations as a viable strategy for precise drug dosing in pediatrics: propranolol case study
Abstract
The development of solid dosage forms that are both convenient for administration and allow precise drug dosing for pediatric patients is one of the great challenges in contemporary pharmaceutical technology. The presented study has utilized propranolol hydrochloride, as one of the most frequently prescribed drugs that require manipulation of the conventional dosage forms to be administered to children. Multiparticulate oral formulations, powder- and granule-filled capsules, as well as mini tablets, were prepared and characterized in terms of their mass and content uniformity and compared to conventional marketed tablets split into halves and quarters. The obtained results have demonstrated the superiority of the multiparticulate formulations, in terms of their average mass and drug content uniformity. It has also been demonstrated that, due to improved flowability, granule-filled capsules are more conveniently compounded and provide higher content uniformity compared to powder-filled capsules. The presented compounding method could be easily employed in community pharmacy settings. Mini tablets with high and uniform content of propranolol hydrochloride have been successfully prepared, thereby presenting a viable strategy for efficient drug dose adjustment.
References
Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J. 2013;15(4):1072-81.
Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: Standards and novel strategies for drug administration in pediatrics. J Clin Pharmacol. 2018;58(S10):S26-S35.
Trofimiuk M, Wasilewska K, Winnicka K. How to modify drug release in paediatric dosage forms? Novel technologies and modern approaches with regard to children’s population. Int J Mol Sci. 2019;20(13):3200.
Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms-challenges and recent developments: A critical review. J Appl Pharm Sci. 2020;10(07):155-66.
European Medicines Agency: EMA/CHMP/QWP/805880/2012 - Guideline on pharmaceutical development of medicines for paediatric use 2013 [Internet] [Cited 2020 April]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinepharmaceutical-development-medicines-paediatric-use_en.pdf.
World Health Organization: QAS/08.257/Rev.3. Geneva, 2011. Annex 5: Development of paediatric medicines: points to consider in formulation [Internet] [Cited 2020 April]. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex5TRS970.pdf?ua=1.
European Medicines Agency: EMEA/CHMP/PEG/194810/2005 - Reflection paper: Formulations of choice for the paediatric population 2006 [Internet] [Cited 2020 April]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf.
European Medicines Agency: EMA/761434/2010 - Report on the survey of all paediatric uses of medicinal products in Europe: Executive summary 2011 [Internet] [Cited 2020 April]. Available from:https://www.ema.europa.eu/en/documents/other/report-survey-all-paediatric-usesmedicinal-products-europe-executive-summary_en.pdf.
Medicines.org.uk. 2020. Propranolol tablets 10 mg BP - Summary of Product Characteristics (SPC) - (Emc) [Internet] [Cited 2020 May 24]. Available from:
https://www.medicines.org.uk/emc/product/5888/smpc.
Alims.gov.rs 2020. Propranolol tablets 40 mg - Summary of Product Characteristics (SPC) - Medicines and Medical Devices Agency of the Republic of Serbia [Internet] [Cited 2020 July 24]. Available from: https://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-01419-17-001.pdf.
European Medicines Agency. Hemangiol 3.75 mg/ml oral solution - Summary of Product Characteristics (SPC). [Internet] [Cited 2020 May 24]. Available from:
https://www.ema.europa.eu/en/documents/product-information/hemangioleparproduct-information_en.pdf
Van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G. Statistical analysis of tablet breakability methods. J Pharm Pharmaceutic Sci. 2002;5(2):190-8.
Van Santen E, Barends DM, Frijlink HW. Breaking of scored tablets: a review. Eur J Pharm Biopharm. 2002;53(2):139-45.
Hill SW, Varker AS, Karlage K, Myrdal PB. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications. J Manag Care Pharm. 2009;15(3):253-61.
Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash). 2002;42(2):195-9.
Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study. Int J Pharm. 2016;514(1):296–307.
Lee HS, Lee JJ, Kim MG, Kim KT, Cho CW, Kim DD, Lee JY. Sprinkle formulations - A review of commercially available product. Asian J Pharm Sci. 2020;15(3):292-310.
Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - A novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78(3):462–9.
Thomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutcliffe AG. Minitablets: New modality to deliver medicines to preschool-aged children. Pediatrics. 2009;123(2):235-8.
Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: Unmet needs and novel approaches. Int J Pharm. 2011;404(1–2):1–9.
Iyire A, Mohammed AR. Multiparticulate systems for paediatric drug delivery. In: Rajabi-Siahboomi AR. Multiparticulate Drug Delivery. New York: Springer; 2017; p. 213-36.
Desitin.de/produkte/orfiril-long/ 2020. Orfiril long 150 mg - Patient information leaflets (PIL) [Internet] Desitin Arzneimittel GmbH [Cited 2020 July 26]. Available https://www.desitin.de/wp-content/uploads/2019/08/Orfiril_long_150mg-300mg_GI.pdf.
Desitin.de/produkte/levetiracetam-desitin/ 2020. Levetiracetam DESITIN 250 mg - Patient information leaflets (PIL) [Internet] Desitin Arzneimittel GmbH [Cited 2020 July 26]. Available from: https://www.desitin.de/wpcontent/uploads/2019/09/Levetiracetam_Desitin_GI.pdf.
Enzym Lefax forte kapseln [Internet] [Cited 2020 July 26]. Available from:
https://www.medikamente-per-klick.de/images/ecommerce/02/56/02563871_2008
06_de_o.pdf.
European Pharmacopoeia (Ph. Eur.). 10th ed, Strasbourg: Council of Europe, 2020.
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, Gorodischer R. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol. 2005;6:775–9.
Paul S, Chang SY, Dun J, Sun WJ; Wang K, Tajarobi P, et al. Comparative analyses of flow and compaction properties of diverse mannitol and lactose grades. Int J Pharm. 2018;546(1-2):39-49.
